TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable
disease. In the last decade results of randomized trials and a subsequent metaanalyses
established transarterial chemoembolization (TACE) or systemic chemotherapy (sorafenib) as
standard of care. However, TACE alone is not a curative approach. The two year survival
following TACE ranges from 31-63% with almost 100% patients developing disease progression
after treatment. There is need to investigate additional therapeutic options that would
consolidate the initial response to TACE. A recent metaanalyses concluded that addition of
high dose radiation to TACE results in 10-35% improvement in two year overall survival.
However as results of metaanalyses were based on studies with small sample size, unclear
randomization procedure and heterogenous dose of radiation, the need for conducting a high
quality randomized study was highlighted The present study is designed to investigate the
role of high dose conformal radiation as consolidation therapy after TACE in patients with
nonmetastatic unresectable HCC.